Kiji-tx website

1 known investors

KIJI Tx develops gene-engineered iPSC-derived MSC cell therapies for treating a broad range of inflammatory diseases, with a lead product using IL10 and CXCR4 transduction. The company works in collaboration with research institutions including CIBER, Fundación Jiménez Díaz, and CIEMAT.